Bone marrow transplantation – how can we maximize cardiac status?
Journal Title: OncoReview - Year 2016, Vol 6, Issue 1
Abstract
Authors and Affiliations
Joseph Carver
Keywords
Related Articles
- EP ID EP78732
- DOI 10.5604/20828691.1198513
- Views 203
- Downloads 0
The effect of lipegfilgrastim on hematopoietic reconstitution and supportive treatment after megachemotherapy with autologous peripheral blood stem cell transplantation in patients with lymphoproliferative malignancies
Megachemotherapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) is a standard treatment option in patients below 70 years of age with multiple myeloma (MM) as well as with relapsed and refractory...
Aromataze inhibitors in the treatment of breast cancer
The main goal for hormonal therapy of breast cancer is to inhibit action of endogenous estrogens to breast cancer cells. Discovery of hormonal receptors and knowledge of their biological role employment to manner hormona...
Arterial hypertension related to sunitinib
Hypertension is a common concomitant disease in patients with renal carcinoma and a frequent complication of sunitinib therapy. Blocking of VEGF-dependent pathway leads to endothelial dysfunction, reduced nitric oxide pr...
The cardiac safety during treatment with sunitinib and sorafenib, multikinase angiogenesis inhibitors
Cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, is most often myocardial systolic dysfunction or arterial and venous thromboembolic events. Essential risk factor seems to be iatrogenic art...
Should a diagnosis of cancer impact the anticoagulant therapy in patients with recurrent thromboembolic disease?
Venous thromboembolism often coexists with cancer, deteriorating patient prognosis. The diagnosis of cancer in patients who suffer from venous thromboembolism may lead to changes in the anticoagulant therapy administered...